CN1426468A - Kcnb:新型钾通道蛋白 - Google Patents

Kcnb:新型钾通道蛋白 Download PDF

Info

Publication number
CN1426468A
CN1426468A CN01808748A CN01808748A CN1426468A CN 1426468 A CN1426468 A CN 1426468A CN 01808748 A CN01808748 A CN 01808748A CN 01808748 A CN01808748 A CN 01808748A CN 1426468 A CN1426468 A CN 1426468A
Authority
CN
China
Prior art keywords
polypeptide
kcnb
amino acid
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01808748A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·穆
斯科特·鲍尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of CN1426468A publication Critical patent/CN1426468A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
CN01808748A 2000-03-03 2001-03-02 Kcnb:新型钾通道蛋白 Pending CN1426468A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18691500P 2000-03-03 2000-03-03
US60/186,915 2000-03-03

Publications (1)

Publication Number Publication Date
CN1426468A true CN1426468A (zh) 2003-06-25

Family

ID=22686808

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01808748A Pending CN1426468A (zh) 2000-03-03 2001-03-02 Kcnb:新型钾通道蛋白

Country Status (12)

Country Link
US (2) US7462465B2 (enExample)
EP (1) EP1266003B1 (enExample)
JP (2) JP2004500825A (enExample)
CN (1) CN1426468A (enExample)
AT (1) ATE538201T1 (enExample)
AU (2) AU2001250794B2 (enExample)
CA (1) CA2401906C (enExample)
ES (1) ES2378417T3 (enExample)
IL (2) IL151564A0 (enExample)
NZ (1) NZ521205A (enExample)
WO (1) WO2001066741A2 (enExample)
ZA (1) ZA200206999B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057846A2 (en) * 2001-12-31 2003-07-17 Algos Therapeutics, Inc. Methods and materials for modulating task-3
WO2005052586A2 (en) * 2003-11-27 2005-06-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 3 (kcnk3)
WO2005075510A1 (en) * 2004-02-04 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 9 (kcnk9)
US12416024B2 (en) 2018-03-29 2025-09-16 Transworld Technologies Inc. Biologically enhanced oil recovery methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2744730B1 (fr) 1996-02-08 1998-04-17 Centre Nat Rech Scient Nouvelle famille de canaux potassium de mammifere, leur clonage et leur utilisation notamment pour le criblage de drogues
EP1051485A1 (en) 1998-01-27 2000-11-15 Smithkline Beecham Plc Trek-1 like two pore potassium channel
EP1090118A2 (en) * 1998-06-26 2001-04-11 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
DE69938667D1 (de) 1998-11-09 2008-06-19 Centre Nat Rech Scient Neue familie von säugetier-kaliumkanälen, ihre klonierung und ihre verwendung, besonders für das drogenscreening
WO2000053628A2 (en) * 1999-03-05 2000-09-14 Smithkline Beecham Plc Genes encoding human potassium channel proteins
US20020137202A1 (en) * 1999-12-21 2002-09-26 Catherine Burgess Novel proteins and nucleic acids encoding same
GB2373500B (en) 2000-02-04 2004-12-15 Aeomica Inc Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1381626A2 (en) 2000-04-06 2004-01-21 Incyte Genomics, Inc. Human transporters and ion channels
AU2001294724A1 (en) 2000-09-25 2002-04-08 Millennium Pharmaceuticals, Inc. 56115, a novel human twik potassium channel and uses therefor

Also Published As

Publication number Publication date
US7462465B2 (en) 2008-12-09
CA2401906A1 (en) 2001-09-13
JP2011115169A (ja) 2011-06-16
ES2378417T3 (es) 2012-04-12
US20080234470A1 (en) 2008-09-25
ZA200206999B (en) 2004-05-31
ATE538201T1 (de) 2012-01-15
NZ521205A (en) 2005-09-30
AU5079401A (en) 2001-09-17
IL151564A (en) 2008-11-03
WO2001066741A9 (en) 2003-03-06
WO2001066741A2 (en) 2001-09-13
WO2001066741A3 (en) 2002-04-04
JP2004500825A (ja) 2004-01-15
EP1266003B1 (en) 2011-12-21
CA2401906C (en) 2011-07-19
AU2001250794B2 (en) 2006-03-02
IL151564A0 (en) 2003-04-10
EP1266003A2 (en) 2002-12-18
US20020102676A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
CN1178952C (zh) 编码与感觉转导有关的g-蛋白偶联受体的核酸
CN1317010A (zh) 编码与感觉转导有关的g－蛋白偶联受体的核酸
CN1150804A (zh) 成纤维细胞生长因子-10
US11155598B2 (en) GPR156 variants and uses thereof
CN1240834C (zh) Ly6h基因
CN1747744A (zh) 使用otx2基因再生和新生视网膜感光细胞
CN1426468A (zh) Kcnb:新型钾通道蛋白
CN1147505C (zh) G蛋白受体htnad29
CN1305527A (zh) 血管发生相关分子
CN1942482A (zh) Nkg2d和ul16受体的蛋白质配体及其用途
CN101039956A (zh) 细胞表面糖蛋白
CN1375503A (zh) 雄激素受体复合物相关蛋白
CN1289366A (zh) 人tsc403基因和人ing1l基因
CN1099423C (zh) 人神经肽受体
CN1412198A (zh) 细胞周期调节蛋白
CN1377409A (zh) Meg－1蛋白
CN1307104A (zh) 一种新的多肽——人磷酸烯醇丙酮酸羧化酶81和编码这种多肽的多核苷酸
CN1251653A (zh) 校正异常基因产物功能的物质
AU6624500A (en) G protein-coupled receptor expressed in brain
CN1300826A (zh) 一种新的多肽－dna聚合酶17和编码这种多肽的多核苷酸
CN1328150A (zh) 一种新的多肽——人β－葡萄糖苷酸酶11.88和编码这种多肽的多核苷酸
HK1038380B (en) Ly6h gene
CN1285405A (zh) 人rip110蛋白及其编码序列
JP2003259884A (ja) 新規ポリペプチド
CN1301869A (zh) 新的人促分裂原活化蛋白激酶磷酸酶及其编码序列

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20030625